bioAffinity Technologies (BIAFW) Stock Price, News & Analysis

Company Overview

bioAffinity Technologies is a biotechnology company focused on developing diagnostic tests for the early detection of lung cancer and other diseases. Its work combines cellular analysis and other diagnostic technologies to support earlier identification of disease.

The company’s lead product, CyPath Lung, is a diagnostic test that analyzes sputum samples using flow cytometry to help assess the likelihood of lung cancer. The test is processed through Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.

Based in San Antonio, Texas, bioAffinity Technologies has focused its commercial and development activities on lung cancer diagnostics. Maria Zannes has served as the company’s president and chief executive officer.

Key Stats

• Today's Range: $0.15 to $0.15
• 50-Day Range: $0.13 to $1.01
• 52-Week Range: $0.05 to $0.98
• Volume: 605 shs
• Average Volume: 4,682 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 11/13/2026
• Next Earnings (Estimated): 11/18/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BIAFW
• CIK: 1712762
• Web: www.bioaffinitytech.com
• Phone: 210 698 5334
• Fax: N/A
• Employees: 57
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $5.85 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A